Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zymeworks Inc (NY: ZYME )

6.430 UNCHANGED
Last Price Updated: 7:00 PM EST, Dec 15, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 6.430
Bid (Size) 5.950 (3)
Ask (Size) 6.750 (1)
Prev. Close 6.430
Today's Range 6.430 - 6.430
52wk Range 4.110 - 9.150
Shares Outstanding 57,771,204
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via Business Wire
$3M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed higher on Monday, there were a few notable insider trades. 
Via Benzinga

Performance

YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
-8.53%
-8.53%
6 Month
+2.72%
+2.72%
1 Year
-23.54%
-23.54%

More News

Read More
Analyst Ratings for Zymeworks BC
Via Benzinga
Jazz Pharma, Zymeworks Highlight 84% Overall Survival At 18 Months From Zanidatamab In Esophageal Cancer
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Starbox Group Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Jazz Pharma Opts In, Advances Zanidatamab Partnership With Zymeworks
Via Benzinga
6 Analysts Have This to Say About Zymeworks BC
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Around $10M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Around $8 Million Bet On Zymeworks? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023
From Zymeworks Inc.
Via Business Wire
Zymeworks Cancer Candidate Shows Objective Response Of 41% In Bile Duct Cancer
Via Benzinga
20 Favorite Biotech & Medical Stocks For 2023
Via Talk Markets
Alphabet To $115? Here Are 10 Other Price Target Changes For Thursday
Via Benzinga
Tesla, Amazon, Micron, Sintx, Zymeworks: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
Zymeworks Announces Participation in Upcoming Investor Conference
From Zymeworks Inc.
Via Business Wire
Why Venus Concept Shares Are Trading Higher By Over 63%? Here Are 58 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022
Via Benzinga
Zymeworks Announces Positive Topline Data in the Pivotal HERIZON-BTC-01 Trial of Zanidatamab
From Zymeworks Inc.
Via Business Wire
Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
From Zymeworks Inc.
Via Business Wire
New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS
From Zymeworks Inc.
Via Business Wire
Zymeworks to Transfer Stock Listing to Nasdaq
From Zymeworks Inc.
Via Business Wire
Big Developments Set to be Unveiled at This Year’s San Antonio Breast Cancer Symposium (SABCS)
Via FinancialNewsMedia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.